California State Teachers Retirement System decreased its holdings in shares of Five Prime Therapeutics Inc (NASDAQ:FPRX) by 9.4% during the second quarter, according to its most recent filing with the SEC. The firm owned 48,175 shares of the biotechnology company’s stock after selling 5,000 shares during the period. California State Teachers Retirement System owned 0.17% of Five Prime Therapeutics worth $1,451,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also bought and sold shares of FPRX. State Street Corp boosted its holdings in shares of Five Prime Therapeutics by 25.7% in the 1st quarter. State Street Corp now owns 1,249,520 shares of the biotechnology company’s stock valued at $45,175,000 after buying an additional 255,488 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Five Prime Therapeutics by 162.9% in the 2nd quarter. JPMorgan Chase & Co. now owns 298,395 shares of the biotechnology company’s stock worth $8,984,000 after purchasing an additional 184,888 shares in the last quarter. Artal Group S.A. acquired a new stake in Five Prime Therapeutics in the 2nd quarter worth approximately $4,517,000. Victory Capital Management Inc. boosted its stake in Five Prime Therapeutics by 28.9% in the 2nd quarter. Victory Capital Management Inc. now owns 666,440 shares of the biotechnology company’s stock worth $20,066,000 after purchasing an additional 149,340 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale boosted its stake in Five Prime Therapeutics by 800.0% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 130,500 shares of the biotechnology company’s stock worth $4,116,000 after purchasing an additional 116,000 shares in the last quarter. 83.80% of the stock is currently owned by institutional investors and hedge funds.
Shares of Five Prime Therapeutics Inc (FPRX) traded down $0.93 during midday trading on Wednesday, reaching $23.64. 582,902 shares of the company traded hands, compared to its average volume of 406,384. Five Prime Therapeutics Inc has a 12 month low of $21.41 and a 12 month high of $58.88.
Five Prime Therapeutics (NASDAQ:FPRX) last issued its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($1.54) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.19). The company had revenue of $8.33 million during the quarter, compared to analysts’ expectations of $16.16 million. Five Prime Therapeutics had a negative return on equity of 41.57% and a negative net margin of 408.42%. Five Prime Therapeutics’s revenue was up 24.7% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.72) EPS. analysts expect that Five Prime Therapeutics Inc will post -5.56 earnings per share for the current year.
FPRX has been the subject of a number of recent analyst reports. Royal Bank Of Canada lifted their target price on shares of Five Prime Therapeutics from $41.00 to $50.00 and gave the stock an “outperform” rating in a research note on Monday, November 6th. Jefferies Group restated a “buy” rating and set a $52.00 price objective on shares of Five Prime Therapeutics in a research note on Tuesday, September 12th. ValuEngine upgraded shares of Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Zacks Investment Research upgraded shares of Five Prime Therapeutics from a “sell” rating to a “buy” rating and set a $49.00 price objective for the company in a research note on Monday, October 16th. Finally, BMO Capital Markets upgraded shares of Five Prime Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Monday, October 16th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $64.00.
In other Five Prime Therapeutics news, Director William R. Ringo sold 2,000 shares of Five Prime Therapeutics stock in a transaction on Thursday, September 28th. The shares were sold at an average price of $38.00, for a total transaction of $76,000.00. Following the sale, the director now owns 2,000 shares of the company’s stock, valued at approximately $76,000. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director William R. Ringo sold 1,800 shares of Five Prime Therapeutics stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $40.26, for a total transaction of $72,468.00. Following the sale, the director now directly owns 1,200 shares in the company, valued at approximately $48,312. The disclosure for this sale can be found here. In the last three months, insiders sold 4,400 shares of company stock valued at $175,666. 6.50% of the stock is owned by insiders.
TRADEMARK VIOLATION WARNING: This report was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another publication, it was stolen and republished in violation of US & international copyright laws. The legal version of this report can be read at https://www.dispatchtribunal.com/2017/12/06/california-state-teachers-retirement-system-sells-5000-shares-of-five-prime-therapeutics-inc-fprx.html.
About Five Prime Therapeutics
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
Receive News & Ratings for Five Prime Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.